Irving, TX 的 轉移性癌症 臨床試驗
11 項針對 轉移性癌症 的研究正在 Irving(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Irving
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
招募中3 期
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center, Irving
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
招募中1 期
- NEXT Oncology Dallas, Irving
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center, Irving
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- NEXT Dallas, Irving
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
招募中1 期
- Next Oncology - Dallas, Irving
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
招募中1/2 期
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center, Irving
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
招募中1/2 期
- Crinetics Study Site, Irving
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
招募中1 期
- NEXT Oncology Dallas, Irving
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
招募中1 期
- NEXT Oncology, Irving
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
招募中1/2 期
- NEXT Dallas, Irving
其他城市的 轉移性癌症 試驗
- Houston, TX104 項研究
- New York City, NY93 項研究
- Nashville, TN70 項研究
- Boston, MA63 項研究
- Los Angeles, CA57 項研究
- St. Louis, MO54 項研究
- Arlington, VA53 項研究
- Philadelphia, PA46 項研究
- Chicago, IL45 項研究
- San Antonio, TX44 項研究
- Washington, DC43 項研究
- Dallas, TX42 項研究
Irving 的其他研究
- 非小細胞肺癌22 項研究
- 癌症(所有類型)15 項研究
- 大腸直腸癌13 項研究
- 乳癌7 項研究
- 胃癌7 項研究
- 胰臟癌7 項研究
- 頭頸部鱗狀細胞癌6 項研究
- 小細胞肺癌6 項研究
- 肺癌6 項研究
- 卵巢癌5 項研究
- 子宮內膜癌4 項研究
- 三陰性乳癌4 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。